Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.04.2015 | short review

A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma

verfasst von: Bahil Ghanim, MD, Mir Alireza Hoda, MD, Thomas Klikovits, MD, Balazs Dome, MD, PhD, Michael Grusch, PhD, Martin Filipits, PhD, Walter Klepetko, MD, Walter Berger, PhD, Balazs Hegedus, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of prognostic and predictive biomarkers in MPM, with a strong emphasis on their applicability in clinical practice.
Vorheriger Artikel Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?
Nächster Artikel Optimal follow-up of ovarian cancer patients
Literatur
1.
Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27(12):2081–90.CrossRefPubMed
2.
van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254–307.PubMedCentralPubMed
3.
Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240–5.CrossRefPubMed
4.
de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413–8.CrossRefPubMed
5.
Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36(6):1362–9.CrossRefPubMed
6.
Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–72.CrossRefPubMedCentralPubMed
7.
Ghanim B, Hoda MA, Klikovits T, Winter MP, Alimohammadi A, Grusch M, et al. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. Br J Cancer. 2014;110(4):984–90.CrossRefPubMedCentralPubMed
8.
Baas P. Predictive and prognostic factors in malignant pleural mesothelioma. Curr Opin Oncol. 2003;15(2):127–30.CrossRefPubMed
9.
Pantazopoulos I, Boura P, Xanthos T, Syrigos K. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J. 2013;41(3):706–15.CrossRefPubMed
10.
Linton A, van Zandwijk N, Reid G, Clarke S, Cao C, Kao S. Inflammation in malignant mesothelioma—friend or foe? Ann Cardiothorac Surg. 2012;1(4):516–22.PubMedCentralPubMed
11.
Ghanim B, Hoda MA, Winter MP, Klikovits T, Alimohammadi A, Hegedus B, et al. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann Surg. 2012;256(2):357–62.CrossRefPubMed
12.
Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, Sharma R. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7(3):587–94.CrossRefPubMed
13.
Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145–52.PubMed
14.
Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723–31.CrossRefPubMed
15.
Baldi A, Santini D, Vasaturo F, Santini M, Vicidomini G, Di Marino MP, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax. 2004;59(5):428–33.CrossRefPubMedCentralPubMed
16.
Bitanihirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, et al. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. J Thorac Oncol. 2014;9(2):239–47.CrossRefPubMed
17.
Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol. 2012;7(1):249–56.CrossRefPubMed
18.
Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 2010;28(9):1534–9.CrossRefPubMed
19.
Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–95.CrossRefPubMed
20.
Stahel RA, Weder W, Lievens Y, Felip E. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):v126–8.
21.
Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55(9):731–5.CrossRefPubMedCentralPubMed
22.
Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011;6(11):1923–9.CrossRefPubMed
23.
Meniawy TM, Creaney J, Lake RA, Nowak AK. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. Br J Cancer. 2013;109(7):1813–20.CrossRefPubMedCentralPubMed
24.
Tanrikulu AC, Abakay A, Kaplan MA, Kucukoner M, Palanci Y, Evliyaoglu O, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration. 2010;80(6):480–7.CrossRefPubMed
25.
Baud M, Strano S, Dechartres A, Jouni R, Triponez F, Chouaid C, et al. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. J Thorac Cardiovasc Surg. 2013;145(5):1305–11.CrossRefPubMed
26.
Nojiri S, Gemba K, Aoe K, Kato K, Yamaguchi T, Sato T, et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol. 2011;41(1):32–9.CrossRefPubMed
27.
Aigner C, Hoda MA, Lang G, Taghavi S, Marta G, Klepetko W. Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2008;34(1):204–7.CrossRefPubMed
28.
Kao SC, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, et al. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer. 2013;14(1):70–7.CrossRefPubMed
29.
Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367(15):1417–27.CrossRefPubMedCentralPubMed
Metadaten
Titel
A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma
verfasst von
Bahil Ghanim, MD
Mir Alireza Hoda, MD
Thomas Klikovits, MD
Balazs Dome, MD, PhD
Michael Grusch, PhD
Martin Filipits, PhD
Walter Klepetko, MD
Walter Berger, PhD
Balazs Hegedus, PhD
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0166-4

Weitere Artikel der Ausgabe 1/2015

Optimal follow-up of endometrial cancer patients

  • short review

Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia

  • short review

Lymphoma: anything new?

  • editorial

To maintain or not to maintain: treatment forever in myeloma?

  • short review

Treatment of myeloma patients with renal impairment

  • short review

Optimal follow-up of ovarian cancer patients

  • short review